Henrik Hasle1, Jan M Friedman2, Jørgen H Olsen3, Sonja A Rasmussen4. 1. Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Medical Genetics, University of British Columbia, Vancouver, Canada. 3. Danish Cancer Society Research Centre, Danish Cancer Society, Copenhagen, Denmark. 4. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
PURPOSE: The aim of this study was to investigate cancer incidence in a large cohort of persons with Down syndrome. METHODS: Down syndrome was identified from the Danish Cytogenetic Register. Cancer occurrence was identified by linkage to the Danish Cancer Registry. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated based on observed and expected numbers from rates for all Danish residents. The cohort consisted of 3,530 persons with Down syndrome contributing 89,570 person-years at risk. RESULTS: Acute leukemia risk was highest from 1-4 years of age and remained elevated until age 30. The overall risk of solid tumors was decreased (SIR 0.45; 95% CI 0.34-0.59), especially in persons 50 years or older (SIR 0.27; 95% CI 0.16-0.43). We found a significantly lower risk of lung cancer (SIR 0.10; 95% CI 0.00-0.56), breast cancer (SIR 0.16; 95% CI 0.03-0.47), and cervical cancer (SIR 0.0; 95% CI 0.00-0.77). Testicular cancer was the only solid tumor with an increased SIR (2.9; 95% CI 1.6-4.8). CONCLUSIONS: The risk of all major groups of solid tumors was decreased, except testicular cancer. Altered screening strategies should be considered for persons with Down syndrome. This unusual pattern of cancer occurrence may help understanding carcinogenesis in the general population.Genet Med 18 11, 1151-1157.
PURPOSE: The aim of this study was to investigate cancer incidence in a large cohort of persons with Down syndrome. METHODS: Down syndrome was identified from the Danish Cytogenetic Register. Cancer occurrence was identified by linkage to the Danish Cancer Registry. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated based on observed and expected numbers from rates for all Danish residents. The cohort consisted of 3,530 persons with Down syndrome contributing 89,570 person-years at risk. RESULTS: Acute leukemia risk was highest from 1-4 years of age and remained elevated until age 30. The overall risk of solid tumors was decreased (SIR 0.45; 95% CI 0.34-0.59), especially in persons 50 years or older (SIR 0.27; 95% CI 0.16-0.43). We found a significantly lower risk of lung cancer (SIR 0.10; 95% CI 0.00-0.56), breast cancer (SIR 0.16; 95% CI 0.03-0.47), and cervical cancer (SIR 0.0; 95% CI 0.00-0.77). Testicular cancer was the only solid tumor with an increased SIR (2.9; 95% CI 1.6-4.8). CONCLUSIONS: The risk of all major groups of solid tumors was decreased, except testicular cancer. Altered screening strategies should be considered for persons with Down syndrome. This unusual pattern of cancer occurrence may help understanding carcinogenesis in the general population.Genet Med 18 11, 1151-1157.
Authors: Andreas Pettersson; Lorenzo Richiardi; Agneta Nordenskjold; Magnus Kaijser; Olof Akre Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Kelly W Maloney; Jeffrey W Taub; Yaddanapudi Ravindranath; Irene Roberts; Paresh Vyas Journal: Pediatr Clin North Am Date: 2015-02 Impact factor: 3.278
Authors: Katherine A Waugh; Paula Araya; Ahwan Pandey; Kimberly R Jordan; Keith P Smith; Ross E Granrath; Santosh Khanal; Eric T Butcher; Belinda Enriquez Estrada; Angela L Rachubinski; Jennifer A McWilliams; Ross Minter; Tiana Dimasi; Kelley L Colvin; Dmitry Baturin; Andrew T Pham; Matthew D Galbraith; Kyle W Bartsch; Michael E Yeager; Christopher C Porter; Kelly D Sullivan; Elena W Hsieh; Joaquin M Espinosa Journal: Cell Rep Date: 2019-11-12 Impact factor: 9.423
Authors: Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan Journal: Cell Rep Date: 2020-11-17 Impact factor: 9.423
Authors: Oguzhan Alagoz; Ali Hajjar; Sarocha Chootipongchaivat; Nicolien T van Ravesteyn; Jennifer M Yeh; Mehmet Ali Ergun; Harry J de Koning; Brian Chicoine; Barry Martin Journal: J Gen Intern Med Date: 2019-08-05 Impact factor: 5.128
Authors: Robert E Goldsby; Kayla L Stratton; Shannon Raber; Arthur Ablin; Louise C Strong; Kevin Oeffinger; Charles A Sklar; Gregory T Armstrong; Leslie L Robison; Smita Bhatia; Wendy M Leisenring Journal: Cancer Date: 2017-11-03 Impact factor: 6.860